As shown in Figure 3A, the mean GSK3β levels are ~2-fold increased in the PBMCs in the DM1 group with moderate muscle weakness relative to those in DM1 patients with shorter CTG expansions and mild muscle weakness. This evidence concerns the gene GSK3B and myotonic dystrophy type 1.